Innogen Pharma jostles for a slice of the weight-loss market
The developer of diabetes and anti-obesity drugs has applied for a Hong Kong IPO as it prepares for battle in a crowded arena Key Takeaways: Innogen is expected to launch…
Recent Articles
RELATED ARTICLES
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK -
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
